Your PDF has successfully downloaded.

You may be interested in finding more content on these topics:


You are not currently logged in.

Access JSTOR through your library or other institution:


Log in through your institution.

Mast cell number, phenotype, and function in human pulmonary arterial hypertension

Samar Farha, Jacqueline Sharp, Kewal Asosingh, Margaret Park, Suzy A. A. Comhair, W. H. Wilson Tang, Jim Thomas, Carol Farver, Fred Hsieh, James E. Loyd and Serpil C. Erzurum
Pulmonary Circulation
Vol. 2, No. 2 (April 2012), pp. 220-228
DOI: 10.4103/2045-8932.97609
Stable URL:
Page Count: 9
  • Download PDF
  • Add to My Lists
  • Cite this Item
We're having trouble loading this content. Download PDF instead.


AbstractA proliferation of mast cells around the small pulmonary blood vessels and the alveolar septae has been noted in models of pulmonary hypertension, and in plexiform lesions of pulmonary arterial hypertension (PAH) in patients. Here, we hypothesize that total mast cell numbers and activation are increased in PAH and that they contribute to vascular remodeling through cellular and soluble proangiogenic effectors. To test this, blood and urine were collected from patients with PAH (N=44), asthma (N=18) and healthy controls (N=29) to quantitate biomarkers of total body mast cell numbers and activation (total and mature tryptase, N-methyl histamine, leukotriene LTE4 and prostaglandin PGD-M). Serum total tryptase was higher in PAH than that in controls suggesting greater numbers of mast cells, but indicators of mast cell activation (mature tryptase, LTE4 and PGD-M) were similar among PAH, asthma, and controls. Immunohistochemistry of lung tissues identified mast cells as primarily perivascular and connective tissue chymase+ type in PAH, rather than mucosal phenotype. Intervention with mast cell inhibitors cromolyn and fexofenadine was performed in 9 patients for 12 weeks to identify the influence of mast cell products on the pathologic proangiogenic environment. Treatment decreased total tryptase and LTE-4 levels over time of treatment. This occurred in parallel to a drop in vascular endothelial growth factor (VEGF) and circulating proangiogenic CD34+CD133+ progenitor cells, which suggests that mast cells may promote vascular remodeling and dysfunction. In support of this, levels of exhaled nitric oxide, a vasodilator that is generally low in PAH, increased at the end of the 12-week mast cell blockade and antihistamine. These results suggest that mast cells might contribute to the pulmonary vascular pathologic processes underlying PAH. More studies are needed to confirm their potential contribution to the disease.

Notes and References

This item contains 38 references.

  • 1.
    ['Farber HW, Loscalzo J. Pulmonary arterial hypertension. The New England journal of medicine 2004;351:1655–65.']
  • 2.
    ['Humbert M, McLaughlin VV. The 4th World Symposium on Pulmonary Hypertension. Introduction. J Am Coll Cardiol 2009;54(1 Suppl):S1–2.']
  • 3.
    ['McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation 2006;114:1417–31.']
  • 4.
    ['Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010;122:156–63.']
  • 5.
    ['Ghofrani HA, Barst RJ, Benza RL, Champion HC, Fagan KA, Grimminger F, et al. Future perspectives for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54(1 Suppl):S108–17.']
  • 6.
    ['Theoharides TC. Mast cells and pancreatic cancer. N Engl J Med 2008;358:1860–1.']
  • 7.
    ['Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, Werb Z, et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes & development 1999;13:1382–97.']
  • 8.
    ['Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiological reviews 1997;77:1033–79.']
  • 9.
    ['Heath D, Yacoub M. Lung mast cells in plexogenic pulmonary arteriopathy. J Clin Pathol 1991;44:1003–6.']
  • 10.
    ['Dahal BK, Kosanovic D, Kaulen C, Cornitescu T, Savai R, Hofmann J, et al. Involvement of mast cells in monocrotaline-induced pulmonary hypertension in rats. Respir Res 2011;12:60.']
  • 11.
    ['Tucker A, McMurtry IF, Alexander AF, Reeves JT, Grover RF. Lung mast cell density and distribution in chronically hypoxic animals. J Appl Physiol 1977;42:174–8.']
  • 12.
    ['van Albada ME, Bartelds B, Winberg H, Mohaupt S, Dickinson MG, Schoemaker RG, et al. Gene expression profile in flow-associated pulmonary arterial hypertension with neointimal lesions. Am J Physiol Lung Cell Mol Physiol 2010;298:L483–91.']
  • 13.
    ['Nadziejko CE, Loud AV, Kikkawa Y. Effect of alveolar hypoxia on pulmonary mast cells in vivo. The American review of respiratory disease 1989;140:743–8.']
  • 14.
    ['Blair RJ, Meng H, Marchese MJ, Ren S, Schwartz LB, Tonnesen MG, et al. Human mast cells stimulate vascular tube formation. Tryptase is a novel, potent angiogenic factor. J Clin Invest 1997;99:2691–700.']
  • 15.
    ['Ribatti D, Vacca A, Nico B, Crivellato E, Roncali L, Dammacco F. The role of mast cells in tumour angiogenesis. Br J Haematol 2001;115:514–21.']
  • 16.
    ['Mitani Y, Ueda M, Maruyama K, Shimpo H, Kojima A, Matsumura M, et al. Mast cell chymase in pulmonary hypertension. Thorax 1999;54:88–90.']
  • 17.
    ['Hamada H, Terai M, Kimura H, Hirano K, Oana S, Niimi H. Increased expression of mast cell chymase in the lungs of patients with congenital heart disease associated with early pulmonary vascular disease. Am J Respir Crit Care Med 1999;160:1303–8.']
  • 18.
    ['Maltby S, Khazaie K, McNagny KM. Mast cells in tumor growth: angiogenesis, tissue remodelling and immune-modulation. Biochimica et biophysica acta 2009;1796:19–26.']
  • 19.
    ['Kishi K, Jin D, Takai S, Muramatsu M, Katayama H, Tamai H, et al. Role of chymase-dependent angiotensin II formation in monocrotaline-induced pulmonary hypertensive rats. Pediatr Res 2006;60:77–82.']
  • 20.
    ['Hoffmann J, Yin J, Kukucka M, Yin N, Saarikko I, Sterner-Kock A, et al. Mast cells promote lung vascular remodelling in pulmonary hypertension. Eur Respir J 2011;37:1400–10.']
  • 21.
    ['Gambaryan N, Perros F, Montani D, Cohen-Kaminsky S, Mazmanian M, Renaud JF, et al. Targeting of c-kit+ haematopoietic progenitor cells prevents hypoxic pulmonary hypertension. Eur Respir J 2011;37:1392–9.']
  • 22.
    ['Banasova A, Maxova H, Hampl V, Vízek M, Povýsilová V, Novotná J, et al. Prevention of mast cell degranulation by disodium cromoglycate atenuates the development of hypoxic pulmonary hypertension in rats exposed to chronic hypoxia. Respiration 2008;76:102–7.']
  • 23.
    ['Montani D, Perros F, Gambaryan N, Girerd B, Dorfmuller P, Price LC, et al. C-kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2011;184:116–23.']
  • 24.
    ['Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005;26:720–35.']
  • 25.
    ['ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 2005;171:912–30.']
  • 26.
    ['Schwartz LB, Bradford TR, Rouse C, Irani AM, Rasp G, Van der Zwan JK, et al. Development of a new, more sensitive immunoassay for human tryptase: Use in systemic anaphylaxis. J Clin Immunol 1994;14:190–204.']
  • 27.
    ['Martens-Lobenhoffer J, Neumann HJ. Determination of 1-methylhistamine and 1-methylimidazoleacetic acid in human urine as a tool for the diagnosis of mastocytosis. J Chromatogr B Biomed Sci Appl 1999;721:135–40.']
  • 28.
    ['Awad JA, Morrow JD, Roberts LJ 2nd. Simplification of the mass spectrometric assay for the major urinary metabolite of prostaglandin D2. J Chromatogr 1993;617:124–8.']
  • 29.
    ['Asosingh K, Aldred MA, Vasanji A, Drazba J, Sharp J, Farver C et al. Circulating angiogenic precursors in idiopathic pulmonary arterial hypertension. Am J Pathol 2008;172:615–27.']
  • 30.
    ['Ghofrani HA, Morrell NW, Hoeper MM, Olschewski H, Peacock AJ, Barst RJ, et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 2010;182:1171–7.']
  • 31.
    ['Bartelds B, van Loon RL, Mohaupt S, Winberg H, Dickinson MG, Boersma B, et al. Mast cell inhibition improves pulmonary vascular remodeling in pulmonary hypertension. Chest 2012;141:651–60.']
  • 32.
    ['Ozkan M, Dweik RA, Laskowski D, Arroliga AC, Erzurum SC. High levels of nitric oxide in individuals with pulmonary hypertension receiving epoprostenol therapy. Lung 2001;179:233–43.']
  • 33.
    ['Machado RF, Londhe Nerkar MV, Dweik RA, Hammel J, Janocha A, Pyle J, et al. Nitric oxide and pulmonary arterial pressures in pulmonary hypertension. Free Radic Biol Med 2004;37:1010–7.']
  • 34.
    ['Xu W, Koeck T, Lara AR, Neumann D, DiFilippo FP, Koo M, et al. Alterations of cellular bioenergetics in pulmonary artery endothelial cells. Proc Natl Acad Sci U S A 2007;104:1342–7.']
  • 35.
    ['Xu W, Kaneko FT, Zheng S, Comhair SA, Janocha AJ, Goggans T, et al. Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension. Faseb J 2004;18:1746–8.']
  • 36.
    ['Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. New Eng J Med 1995;333:214–21.']
  • 37.
    ['Guo FH, Comhair SA, Zheng S, Dweik RA, Eissa NT, Thomassen MJ, et al. Molecular mechanisms of increased nitric oxide (NO) in asthma: Evidence for transcriptional and post-translational regulation of NO synthesis. J Immunol 2000;164:5970–80.']
  • 38.
    ['Cowan DC, Hewitt RS, Cowan JO, Palmay R, Williamson A, Lucas SJ, et al. Exercise-induced wheeze: Fraction of exhaled nitric oxide-directed management. Respirology 2010;15:683–90.']